93 related articles for article (PubMed ID: 14992002)
1. [Studies on formulations of Panax notoginsenosides for intranasal administration].
Xu QF; Fang XL; Chen DF; Li JC
Yao Xue Xue Bao; 2003 Nov; 38(11):859-62. PubMed ID: 14992002
[TBL] [Abstract][Full Text] [Related]
2. [The nasal mucosa permeability and toxicity of baicalin carrier systems liposomes, beta-cyclodextrin inclusion compound, and phospholipid complex].
Wu PJ; Xu RC; Su ZT; Wei P; Lin YJ; Yang M; Zheng Q
Yao Xue Xue Bao; 2009 Apr; 44(4):417-24. PubMed ID: 19545062
[TBL] [Abstract][Full Text] [Related]
3. [The pharmacokinetics and pharmacodynamics of intranasal preparation of Panax notoginseng Saponins].
Wu YJ; Zhu XY; Sha XY; Fang XL
Yao Xue Xue Bao; 2005 Apr; 40(4):377-81. PubMed ID: 16011272
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats.
Xu QF; Fang XL; Chen DF
J Ethnopharmacol; 2003 Feb; 84(2-3):187-92. PubMed ID: 12648814
[TBL] [Abstract][Full Text] [Related]
5. [Effect of absorption enhancers on nasal ginsenoside Rg1 delivery and its nasal ciliotoxicity].
Chen XM; Zhu JB; Sun WD; Zhang LJ
Yao Xue Xue Bao; 2006 Feb; 41(2):149-55. PubMed ID: 16671546
[TBL] [Abstract][Full Text] [Related]
6. Brain distribution pharmacokinetics and integrated pharmacokinetics of Panax Notoginsenoside R1, Ginsenosides Rg1, Rb1, Re and Rd in rats after intranasal administration of Panax Notoginseng Saponins assessed by UPLC/MS/MS.
Guo Q; Li P; Wang Z; Cheng Y; Wu H; Yang B; Du S; Lu Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Oct; 969():264-71. PubMed ID: 25203723
[TBL] [Abstract][Full Text] [Related]
7. The use of lipid-based formulations to increase the oral bioavailability of Panax notoginseng saponins following a single oral gavage to rats.
Xiong J; Guo J; Huang L; Meng B; Ping Q
Drug Dev Ind Pharm; 2008 Jan; 34(1):65-72. PubMed ID: 18214757
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs.
Marttin E; Verhoef JC; Merkus FW
J Drug Target; 1998; 6(1):17-36. PubMed ID: 9769018
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism of oral absorption of panaxnotoginseng saponins].
Han M; Han LM; Wang QS; Bai ZH; Fang XL
Yao Xue Xue Bao; 2006 Jun; 41(6):498-505. PubMed ID: 16927822
[TBL] [Abstract][Full Text] [Related]
10. [Screening of Panax notoginsenoside water in oil microemulsion formulations and their evaluation in vitro and in vivo].
Han M; Fu S; Fang XL
Yao Xue Xue Bao; 2007 Jul; 42(7):780-6. PubMed ID: 17882965
[TBL] [Abstract][Full Text] [Related]
11. Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats.
Bshara H; Osman R; Mansour S; El-Shamy Ael-H
Carbohydr Polym; 2014 Jan; 99():297-305. PubMed ID: 24274510
[TBL] [Abstract][Full Text] [Related]
12. Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats.
Khan S; Patil K; Yeole P; Gaikwad R
J Pharm Pharmacol; 2009 May; 61(5):669-75. PubMed ID: 19406007
[TBL] [Abstract][Full Text] [Related]
13. HPLC determination of four active saponins from Panax notoginseng in rat serum and its application to pharmacokinetic studies.
Li L; Sheng Y; Zhang J; Wang C; Guo D
Biomed Chromatogr; 2004 Dec; 18(10):849-56. PubMed ID: 15484230
[TBL] [Abstract][Full Text] [Related]
14. Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-beta-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics.
Schipper NG; Verhoef JC; De Lannoy LM; Romeijn SG; Brakkee JH; Wiegant VM; Gispen WH; Merkus FW
Br J Pharmacol; 1993 Dec; 110(4):1335-40. PubMed ID: 8306072
[TBL] [Abstract][Full Text] [Related]
15. [Study on therapeutic window of opportunity for Panax notoginseng saponins following focal cerebral ischemia/reperfusion injury in rats].
He W; Zhu Z; Liu J; Ye H; Zeng J; Huang X; Lai F
Zhong Yao Cai; 2004 Jan; 27(1):25-7. PubMed ID: 15179785
[TBL] [Abstract][Full Text] [Related]
16. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies.
Yu S; Zhao Y; Wu F; Zhang X; Lü W; Zhang H; Zhang Q
Int J Pharm; 2004 Aug; 281(1-2):11-23. PubMed ID: 15288339
[TBL] [Abstract][Full Text] [Related]
17. Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies.
Yang T; Hussain A; Paulson J; Abbruscato TJ; Ahsan F
Pharm Res; 2004 Jul; 21(7):1127-36. PubMed ID: 15290851
[TBL] [Abstract][Full Text] [Related]
18. Difference in oral absorption of ginsenoside Rg1 between in vitro and in vivo models.
Han M; Fang XL
Acta Pharmacol Sin; 2006 Apr; 27(4):499-505. PubMed ID: 16539852
[TBL] [Abstract][Full Text] [Related]
19. Self-micelle formation and the incorporation of lipid in the formulation affect the intestinal absorption of Panax notoginseng.
Xiong J; Guo J; Huang L; Meng B; Ping Q
Int J Pharm; 2008 Aug; 360(1-2):191-6. PubMed ID: 18502060
[TBL] [Abstract][Full Text] [Related]
20. A systematic study of the dissolution and relative bioavailability of four ginsenosides in the form of ultrafine granular powder, common powder and traditional pieces of Panax quinquefolius L, in vitro and in beagles.
Chen S; Xu HQ; Zhang J; Wang CX; Liu JQ; Peng LH; Cheng JL; Liu A
J Ethnopharmacol; 2016 Jun; 185():9-16. PubMed ID: 26976765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
